EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma

Shuncang Zhu, Yinhao Chen, Hongyi Lin, Jinpeng Lu, Yu Pan, Ge Li, Yongding Wu, Haoxiang Zhang, Xiaoxiao Huang, Yiting Chen, Huangjing Chen, Long Jin und 7 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202508431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Shuncang Zhu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Cellular Senescence. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Province Science and Technology Innovation Joint Fund Project, Major Scientific Research Project of Young and Middle-aged people of Fujian Provincial Health Commission, Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination chemotherapy and immunotherapy have failed to achieve breakthroughs in pancreatic ductal adenocarcinoma (PDAC). Chemotherapy‐induced senescence is a potential solution for this problem. This study integrates clinical samples with single‐cell transcriptomic sequencing, proteomics, and RNA sequencing and reveals that FOLFIRINOX (a combination regimen of 5‐fluorouracil, oxaliplatin, irinotecan, and leucovorin) treatment induces a higher proportion of senescent tumor cells (senTCs). This phenomenon is principally attributed to the presence of cCCT2, which inhibits SLX4 condensate‐mediated DNA damage repair pathways by regulating small ubiquitin‐like modifier conjugation, thereby promoting tumor cell senescence. In the tumor immune microenvironment, cCCT2‐overexpressing senTCs exhibit a senescence‐associated secretory phenotype (SASP) with preferential secretion of CXCL10, which induces chemotaxis of CD8 + T‐cells. Based on the pro‐senescence and immune‐microenvironment‐remodeling effects of cCCT2, an engineered exosome‐loaded circRNA system, SenExo‐cCCT2 is developed. When combined with SenExo‐cCCT2, the FOLFIRINOX regimen enhances the capacity of pancreatic cancer cells to induce senescence. Subsequently, anti‐PD‐L1 therapy facilitates the immune‐mediated clearance of senTCs, markedly improving the therapeutic efficacy of combined chemotherapy and immunotherapy for pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCellular SenescenceHumansOxaliplatinIrinotecanFluorouracilLeucovorinTumor MicroenvironmentCell Line, TumorMiceAnimals

Stichwörter der Autor:innen

CD8+ T‐cellschemotherapycircRNApancreatic ductal adenocarcinomasenescence

Substanzen

OxaliplatinIrinotecanfolfirinoxFluorouracilLeucovorin

Autor:innen und Institutionen

  • Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, P. R. China.
  • Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou University, Fuzhou, 350001, P. R. China.
  • Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, P. R. China.
  • Department of Hepatobiliary Surgery, Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, P. R. China.
  • Fuzhou University, Fuzhou, 350001, P. R. China.
  • College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350108, P. R. China.

ORCID-Profile: Shi Chen

Förderung

  • Fujian Province Science and Technology Innovation Joint Fund Project
  • Major Scientific Research Project of Young and Middle-aged people of Fujian Provincial Health Commission
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • Fujian Provincial Science and Technology Innovation Joint Fund Project
  • Natural Science Foundation of Fujian Province, Youth Program
  • National Natural Science Foundation of China
  • Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare

Zitieren

APA

Zhu, S., Chen, Y., Lin, H., Lu, J., Pan, Y., Li, G., Wu, Y., Zhang, H., Huang, X., Chen, Y., Chen, H., Jin, L., Huang, M., Liao, C., Huang, L., Tian, Y., Wang, Z., Li, Q., & Chen, S. (2025). SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.202508431

Vancouver

Zhu S, Chen Y, Lin H, Lu J, Pan Y, Li G, et al. SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Advanced Science. 2025. doi:10.1002/advs.202508431

BibTeX
@article{Zhu2025,
  author = {Zhu, Shuncang and Chen, Yinhao and Lin, Hongyi and Lu, Jinpeng and Pan, Yu and Li, Ge and Wu, Yongding and Zhang, Haoxiang and Huang, Xiaoxiao and Chen, Yiting and Chen, Huangjing and Jin, Long and Huang, Min and Liao, Chengyu and Huang, Long and Tian, Yifeng and Wang, Zuwei and Li, Qiaowei and Chen, Shi},
  title = {SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202508431}
}
Kostenlos starten →